{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T02:26:13Z","timestamp":1794018373155,"version":"4.8.0"},"reference-count":42,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2026,9,12]],"date-time":"2026-09-12T00:00:00Z","timestamp":1789171200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,9,12]],"date-time":"2026-09-12T00:00:00Z","timestamp":1789171200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Universit\u00e4tsklinikum des Saarlandes und Medizinische Fakult\u00e4t der Universit\u00e4t des Saarlandes","id":[{"id":"https:\/\/ror.org\/01jdpyv68","id-type":"ROR","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Neural Transm"],"published-print":{"date-parts":[[2026,10]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>COMT inhibitors (COMT-Is) have now been established for thirty years as adjunctive medication in the treatment of Parkinson\u2019s disease (PD). When they were first introduced, the prolonged duration of action of levodopa and the increase in levodopa levels were regarded as significant advances. Many questions regarding their practical application have not been fully addressed scientifically. This has led to a degree of uncertainty regarding the assessment of the efficacy and, consequently, the use of COMT-Is. For this reason, the aim of this Delphi consensus was to assess the current status of COMT inhibition in PD in Germany, to identify any shortcomings, and to find new approaches to close our knowledge gaps and reach a consensus on recommendations. In doing so, the authors who formulated the questions for the Delphi consensus aim to provide their colleagues with practical guidance on the use of COMT-Is in the treatment of Parkinson\u2019s symptoms. To achieve this aim, 200 specialists in movement disorders across Germany were asked to evaluate 22 statements across three subject areas. 115 specialists responded. Key findings: In topic area 1, \u2018Response fluctuations and the use of COMT-Is\u2019, it emerged that the Wearing-off Questionnaire, 9-item version (WOQ-9) was not unanimously regarded as a suitable tool for diagnosing response fluctuations (agreement rate: 64%). In topic area 2 (role of COMT-Is in the treatment of fluctuations in efficacy), there was a contradiction in that while COMT-Is were not considered the first-line treatment of choice (agreement rate 58%), respondents agreed that they should be used at an early stage when fluctuations in efficacy occur (agreement rate 95%). In topic area 3 (comparison of various aspects of individual COMT-Is), opicapone was unanimously rated as the easiest to manage in daily use due to its once-daily dosing and favourable safety profile (agreement rate: 83%). In summary, the survey provides significant insights into fluctuations diagnosis and the current role of COMT-I in the treatment of PD. The efficacy and tolerability\/safety of opicapone observed in clinical trials for the treatment of Parkinson\u2019s patients with motor fluctuations are also confirmed in this survey in clinical practice.<\/jats:p>","DOI":"10.1007\/s00702-026-03278-x","type":"journal-article","created":{"date-parts":[[2026,9,12]],"date-time":"2026-09-12T12:10:49Z","timestamp":1789215049000},"page":"2993-3003","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["German Delphi consensus: COMT inhibitors in the management of wearing-off fluctuations in Parkinson\u2019s disease"],"prefix":"10.1007","volume":"133","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8574-3297","authenticated-orcid":false,"given":"W. H.","family":"Jost","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.","family":"M\u00fcller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.","family":"Sch\u00fcle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Storch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K.","family":"Witt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.","family":"T\u00f6nges","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,9,12]]},"reference":[{"issue":"18","key":"3278_CR9","first-page":"8850","volume":"27","author":"A Antonini","year":"2023","unstructured":"Antonini A, Barone P, Calabresi P, Lopiano L, Morgante F, Pontieri FE, Sensi M, Stocchi F (2023) The role of opicapone in the management of Parkinson\u2019s disease: an Italian consensus through a combined Nominal Group Technique and Delphi approach. Eur Rev Med Pharmacol Sci 27(18):8850\u20138859","journal-title":"Eur Rev Med Pharmacol Sci"},{"key":"3278_CR14","unstructured":"Brunton LL et al (eds) Goodman and Gilman\u2019s The Pharmacological Basis of Therapeutics, 13th edn. New York, NY, USA: McGraw-Hill Education. 2018:225\u201342, 327\u2013338"},{"key":"3278_CR35","unstructured":"Ceballos-Baumann A, Eggert K, Ferreira J, Poewe W, Rascol O, Arbe E (2018) Rocha J\u2010F, Soares\u2010da\u2010Silva P. Occurrence of dopaminergic adverse events in patients who switched from entacapone to opicapone: The BIPARK-I open-label experience. MDS Congress : Abstract 302"},{"issue":"3","key":"3278_CR30","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1016\/S1474-4422(06)70373-8","volume":"5","author":"KR Chaudhuri","year":"2006","unstructured":"Chaudhuri KR et al (2006) Non-motor symptoms of Parkinson\u2019s disease: diagnosis and management. Lancet Neurol 5(3):235\u2013245","journal-title":"Lancet Neurol"},{"issue":"5","key":"3278_CR34","doi-asserted-by":"publisher","first-page":"776","DOI":"10.1002\/mds.30162","volume":"40","author":"RMA De Bie","year":"2025","unstructured":"De Bie RMA, Katzenschlager R, Swinnen BEKS, Peball M, Lim SY, Mestre TA, Perez Lloret S, Coelho M, Aquino C, Tan AH, Bruno V, Dijk JM, Heim B, Lin CH, Kauppila LA, Litvan I, Spijker R, Seppi K, Costa J, Sampaio C, Fox SH, Silverdale MA (2025) Update on Treatments for Parkinson\u2019s Disease Motor Fluctuations \u2013 An International Parkinson and Movement Disorder Society Evidence-Based Medicine Review. Mov Disord 40(5):776\u2013794","journal-title":"Mov Disord"},{"key":"3278_CR36","doi-asserted-by":"crossref","unstructured":"Ebersbach G, Rascol O, Ferreira J, Costa R, Rocha JF, Magalh\u2009~\u2009aes D, Soares-da-Silva P (2020) Efficacy and safety of opicapone in Parkinson\u2019s disease patients according to duration of motor fluctuations: Post-hoc analysis of BIPARK-I and II [abstract 993]. Mov Disord. ; 35 (suppl 1).","DOI":"10.1016\/j.parkreldis.2020.06.236"},{"issue":"2","key":"3278_CR20","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1016\/S1474-4422(15)00336-1","volume":"15","author":"JJ Ferreira","year":"2016","unstructured":"Ferreira JJ, Lees A, Rocha JF, Poewe W, Rascol O, Soares-da-Silva P (2016) Bi-Park 1 investigators. Opicapone as an adjunct to levodopa in patients with Parkinson\u2019s disease and end-of-dose motor fluctuations: a randomised, double-blind, controlled trial. Lancet Neurol 15(2):154\u2013165","journal-title":"Lancet Neurol"},{"key":"3278_CR41","unstructured":"Ferreira J, Lees A, Rascol O, Poewe W, Santos A, Oliveira I, Hernandez B, Rocha JF (2017) Soares-da-Silva P. How to switch to Opicapone from Entacapone based on experience in the BIPARK-I study. MDS Congress : Abstract 1427"},{"key":"3278_CR42","doi-asserted-by":"publisher","unstructured":"Ferreira JJ, Lees AJ, Poewe W, Rascol O, Rocha JF, Keller B, Soares-da-Silva P (2018) Effectiveness of opicapone and switching from entacapone in fluctuating Parkinson disease. Neurology. ;90(21):e1849-e1857. https:\/\/doi.org\/10.1212\/WNL.0000000000005557. PMID: 29695590","DOI":"10.1212\/WNL.0000000000005557"},{"issue":"11","key":"3278_CR19","doi-asserted-by":"publisher","first-page":"2272","DOI":"10.1002\/mds.29193","volume":"37","author":"JJ Ferreira","year":"2022","unstructured":"Ferreira JJ, Poewe W, Rascol O, Stocchi F, Antonini A, Moreira J, Guimar\u00e3es B, Rocha JF (2022) Soares-da-Silva P. Effect of opicapone on levodopa pharmacokinetics in patients with fluctuating Parkinson\u2019s disease. Mov Disord 37(11):2272\u20132283","journal-title":"Mov Disord"},{"issue":"10","key":"3278_CR23","doi-asserted-by":"publisher","first-page":"6729","DOI":"10.1007\/s00415-024-12614-8","volume":"271","author":"JJ Ferreira","year":"2024","unstructured":"Ferreira JJ, Lee JY, Ma HI, Jeon B, Poewe W, Antonini A, Stocchi F, Rodrigues DM, Fonseca MM, Castilla-Fern\u00e1ndez G, Holenz J, Rocha JF, Rascol O (2024) ADOPTION study investigators. Opicapone for the treatment of early wearing-off in levodopa-treated Parkinson\u2019s disease: a pooled analysis of patient-level data from two randomised open-label studies. J Neurol 271(10):6729\u20136738","journal-title":"J Neurol"},{"issue":"1","key":"3278_CR29","first-page":"87","volume":"15","author":"JJ Ferreira","year":"2025","unstructured":"Ferreira JJ, Gago MF, Costa R, Fonseca MM, Almeida J, Rocha JF, Holenz J, Trenkwalder C (2025) Opicapone for Parkinson\u2019s disease-related sleep disturbances: The OASIS clinical trial. J Park Dis 15(1):87\u201396","journal-title":"J Park Dis"},{"key":"3278_CR1","unstructured":"H\u00f6glinger G et al (2023) Parkinson\u2019s disease, S2k guideline, in: German Society of Neurology (ed.), Guidelines for diagnosis and treatment in neurology: www.dgn.org\/leitlinien (accessed on 20 April 2026)"},{"key":"3278_CR40","first-page":"648","volume":"126","author":"S Huber","year":"2019","unstructured":"Huber S, Altmann C, Benz P, Fleiner A, Wendler P, Jost W (2019) Effects of opicapone at different times of the evening. J Neural Transm 126:648","journal-title":"J Neural Transm"},{"key":"3278_CR17","doi-asserted-by":"publisher","first-page":"1149615","DOI":"10.3389\/fneur.2023.1149615","volume":"14","author":"A Kakimoto","year":"2023","unstructured":"Kakimoto A, Kawazoe M, Kurihara K, Mishima T, Tsuboi Y (2023) Impact of non-motor fluctuations on QOL in patients with Parkinson\u2019s disease. Front Neurol 14:1149615. https:\/\/doi.org\/10.3389\/fneur.2023.1149615","journal-title":"Front Neurol"},{"key":"3278_CR12","doi-asserted-by":"publisher","first-page":"896","DOI":"10.1016\/S0140-6736(14)61393-3","volume":"386","author":"LV Kalia","year":"2015","unstructured":"Kalia LV, Lang AE (2015) Parkinson\u2019s disease. Lancet 386:896\u2013912","journal-title":"Lancet"},{"issue":"6","key":"3278_CR22","doi-asserted-by":"publisher","first-page":"655","DOI":"10.1002\/mdc3.14030","volume":"11","author":"JY Lee","year":"2024","unstructured":"Lee JY, Ma HI, Ferreira JJ, Rocha JF, Sung YH, Song IU, Ahn TB, Kwon DY, Cheon SM, Kim JM, Lee CS, Lee PH, Park JH, Lee JH, Park MY, Kim SJ, Baik JS, Choi SM, Shin HW, Lee HW, Kang SY, Jeon B (2024) Opicapone to treat early wearing-off in Parkinson\u2019s disease patients: The Korean ADOPTION Trial. Mov Disord Clin Pract 11(6):655\u2013665","journal-title":"Mov Disord Clin Pract"},{"key":"3278_CR25","doi-asserted-by":"crossref","unstructured":"Lees A, Ferreira JJ, Reichmann H, Tolosa E, Santos A, Oliveira C, Oliveira I, Lopes N, Rocha JF (2016) Soares-da-Silva P. Opicapone\u2019s onset and stabilisation of treatment effects in Parkinson\u2019s disease patients with motor fluctuations. MDS : Poster 1954","DOI":"10.1016\/j.parkreldis.2015.10.221"},{"issue":"2","key":"3278_CR31","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1001\/jamaneurol.2016.4703","volume":"74","author":"AJ Lees","year":"2017","unstructured":"Lees AJ, Ferreira J, Rascol O, Poewe W, Rocha JF, McCrory M, Soares-da-Silva P et al (2017) Opicapone as an adjunct to levodopa therapy in patients with Parkinson\u2019s disease and motor fluctuations: a randomised clinical trial. JAMA Neurol 74(2):197\u2013206","journal-title":"JAMA Neurol"},{"key":"3278_CR37","doi-asserted-by":"publisher","first-page":"733","DOI":"10.3233\/JPD-191593","volume":"9","author":"A Lees","year":"2019","unstructured":"Lees A, Ferreira JJ, Rocha JF, Rascol O, Poewe W, Gama H, Soares-da-Silva P (2019) Safety profile of opicapone in the management of Parkinson\u2019s disease. J Parkinson Dis 9:733\u2013740. 10.3233","journal-title":"J Parkinson Dis"},{"issue":"7","key":"3278_CR27","doi-asserted-by":"publisher","first-page":"925","DOI":"10.1007\/s00702-023-02603-y","volume":"130","author":"V Leta","year":"2023","unstructured":"Leta V, van Wamelen DJ, Aureli F, Metta V, Trivedi D, Cortelli P, Rodriguez-Blazquez C, Rizos A, Ray Chaudhuri K (2023) The real-life effect of catechol-O-methyltransferase inhibition on non-motor symptoms in levodopa-treated Parkinson\u2019s disease: opicapone versus entacapone. J Neural Transm (Vienna) 130(7):925\u2013930","journal-title":"J Neural Transm (Vienna)"},{"key":"3278_CR4","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1002\/mds.26082","volume":"30","author":"PA LeWitt","year":"2015","unstructured":"LeWitt PA (2015) Levodopa therapy for Parkinson\u2019s disease: Pharmacokinetics and pharmacodynamics. Mov Disord 30:64\u201372","journal-title":"Mov Disord"},{"key":"3278_CR2","first-page":"217","volume":"1","author":"WH Oertel","year":"2011","unstructured":"Oertel WH et al (2011) Early (uncomplicated) Parkinson\u2019s disease. Eur Handb Neurol Manage 1:217\u2013236","journal-title":"Eur Handb Neurol Manage"},{"key":"3278_CR38","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1016\/j.parkreldis.2021.03.031","volume":"86","author":"TL Ong","year":"2021","unstructured":"Ong TL, Dal S, Martin AJ, Chang FC, Williams LJ, Babu S, Mahant N, Morales-Briceno H, Fletcher N, Nankervis J, Robbie M, Fung VSC (2021) Levodopa\/dopa decarboxylase inhibitor-associated microscopic colitis: An under-recognised drug reaction. Parkinsonism Relat Disord 86:84\u201390","journal-title":"Parkinsonism Relat Disord"},{"key":"3278_CR32","doi-asserted-by":"crossref","unstructured":"Pavese N, Lees A, Reichmann H, Martins D, Magalh\u00e3es D, Rocha J, Soares-da-Silva P (2021) Effectiveness of opicapone in Parkinson\u2019s disease patients with motor fluctuations according to baseline use of safinamide: findings from the real-world OPTIPARK study, Mov Disord. ; 36 (suppl 1), S228, abst 526","DOI":"10.1016\/j.jns.2021.119427"},{"key":"3278_CR16","doi-asserted-by":"publisher","first-page":"17013","DOI":"10.1038\/nrdp.2017.13","volume":"3","author":"W Poewe","year":"2017","unstructured":"Poewe W, Seppi K, Tanner C et al (2017) Parkinson disease. Nat Rev Dis Primers 3:17013. https:\/\/doi.org\/10.1038\/nrdp.2017.13","journal-title":"Nat Rev Dis Primers"},{"issue":"11","key":"3278_CR10","doi-asserted-by":"publisher","first-page":"1646","DOI":"10.1002\/mds.23135","volume":"25","author":"M Politis","year":"2010","unstructured":"Politis M, Wu K, Molloy S, Bain PG, Ray Chaudhuri K, Piccini P (2010) Parkinson\u2019s disease symptoms: the patient\u2019s perspective. Mov Disord 25(11):1646\u20131651. https:\/\/doi.org\/10.1002\/mds.23135","journal-title":"Mov Disord"},{"key":"3278_CR7","unstructured":"Product information for Comtess 200\u00a0mg film-coated tablets, version 09\/2024"},{"key":"3278_CR8","unstructured":"Product information for Ongentys 25\u00a0mg\/50\u00a0mg hard capsules, version 03\/2022"},{"key":"3278_CR6","unstructured":"Product information for Tasmar 100\u00a0mg film-coated tablets, version 11\/2022"},{"issue":"6","key":"3278_CR5","doi-asserted-by":"publisher","first-page":"847","DOI":"10.1007\/s00702-023-02623-8","volume":"130","author":"M Regensburger","year":"2023","unstructured":"Regensburger M, Ip CW, Kohl Z, Schrader C, Urban PP, Kassubek J, Jost WH (2023) Clinical benefit of MAO-B and COMT inhibition in Parkinson\u2019s disease: practical considerations. J Neural Transm (Vienna) 130(6):847\u2013861","journal-title":"J Neural Transm (Vienna)"},{"issue":"5","key":"3278_CR21","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1159\/000523771","volume":"85","author":"H Reichmann","year":"2022","unstructured":"Reichmann H, Eggert K, Oehlwein C, Warnecke T, Lees AJ, Kemmer M, Soares-da-Silva P (2022) Opicapone use in clinical practice across Germany: A Sub-Analysis of the OPTIPARK Study in Parkinson\u2019s Disease Patients with Motor Fluctuations. Eur Neurol 85(5):389\u2013397","journal-title":"Eur Neurol"},{"issue":"5","key":"3278_CR26","first-page":"1309","volume":"51","author":"UK Rinne","year":"1998","unstructured":"Rinne UK, Larsen JP, Siden A, Worm-Petersen J (1998) Entacapone enhances the response to levodopa in Parkinson\u2019s disease patients with motor fluctuations. Nomecomt Study Group Neurol 51(5):1309\u20131314","journal-title":"Nomecomt Study Group Neurol"},{"issue":"5","key":"3278_CR24","doi-asserted-by":"publisher","first-page":"763","DOI":"10.1111\/bcp.12081","volume":"76","author":"JF Rocha","year":"2013","unstructured":"Rocha JF, Almeida L, Falc\u00e3o A, Palma PN, Loureiro AI, Pinto R, Bonif\u00e1cio MJ, Wright LC, Nunes T, Soares-da-Silva P (2013) Opicapone: a short-lived and very long-acting novel catechol-O-methyltransferase inhibitor following multiple-dose administration in healthy subjects. Br J Clin Pharmacol 76(5):763\u2013775","journal-title":"Br J Clin Pharmacol"},{"issue":"9","key":"3278_CR18","doi-asserted-by":"publisher","first-page":"1059","DOI":"10.1007\/s00228-014-1701-2","volume":"70","author":"JF Rocha","year":"2014","unstructured":"Rocha JF, Falc\u00e3o A, Santos A, Pinto R, Lopes N, Nunes T, Wright LC, Vaz-da-Silva M, Soares-da-Silva P (2014) Effect of opicapone and entacapone upon levodopa pharmacokinetics during three daily levodopa administrations. Eur J Clin Pharmacol 70(9):1059\u20131071","journal-title":"Eur J Clin Pharmacol"},{"key":"3278_CR39","unstructured":"Santos A, Falc\u00e3o A, Ferreira J, Lees A, Hernandez B, Rocha F, Soares-da-Silva P (2017) Effect of food on opicapone pharmacokinetics and pharmacodynamics. MDS Congress. : Abstract 1428 & Poster"},{"issue":"3","key":"3278_CR28","doi-asserted-by":"publisher","first-page":"383","DOI":"10.3390\/brainsci12030383","volume":"12","author":"D Santos Garc\u00eda","year":"2022","unstructured":"Santos Garc\u00eda D, Garc\u00eda D, Fern\u00e1ndez Pajar\u00edn G, Oropesa-Ruiz JM, Escamilla Sevilla F (2022) Rahim L\u00f3pez RRA, Mu\u00f1oz Enr\u00edquez JG. Brain Sci 12 March 12(3):383. https:\/\/doi.org\/10.3390\/brainsci12030383","journal-title":"Brain Sci 12 March"},{"key":"3278_CR11","doi-asserted-by":"publisher","unstructured":"Stocchi F, Antonini A, Barone P, Tinazzi M, Zappia M, Onofrj M, Ruggieri S, Morgante L, Bonuccelli U, Lopiano L, Pramstaller P, Albanese A, Attar M, Posocco V, Colombo D, Abbruzzese G, DEEP study group (2014). Early DEtection of wEaring off in Parkinson disease: the DEEP study. Parkinsonism Relat Disord. ;20(2):204\u2009\u2013\u200911. https:\/\/doi.org\/10.1016\/j.parkreldis.2013.10.027. Epub 2013 Nov 5. Erratum in: Parkinsonism Relat Disord. 2015;21(7):827. PMID: 24275586","DOI":"10.1016\/j.parkreldis.2013.10.027"},{"issue":"8","key":"3278_CR3","doi-asserted-by":"publisher","first-page":"1239","DOI":"10.2174\/1570159X15666170510143821","volume":"16","author":"N Tambasco","year":"2018","unstructured":"Tambasco N, Romoli R, Calabresi P (2018) Levodopa in Parkinson\u2019s disease: current status and future developments. Curr Neuropharmacol 16(8):1239\u20131252","journal-title":"Curr Neuropharmacol"},{"key":"3278_CR13","doi-asserted-by":"publisher","first-page":"266","DOI":"10.4172\/2157-7099.1000266","volume":"5","author":"FM Werner","year":"2014","unstructured":"Werner FM, Cove\u00f1as R (2014) Classical Neurotransmitters and Neuropeptides involved in Parkinson\u2019s Disease: A Multi-Neurotransmitter System. J Cytol Histol 5:266","journal-title":"J Cytol Histol"},{"issue":"Suppl 11","key":"3278_CR15","doi-asserted-by":"publisher","first-page":"S17","DOI":"10.1002\/mds.20459","volume":"20","author":"K Widnell","year":"2005","unstructured":"Widnell K (2005) Pathophysiology of motor fluctuations in Parkinson\u2019s disease. Mov Disord 20(Suppl 11):S17\u201322","journal-title":"Mov Disord"},{"key":"3278_CR33","doi-asserted-by":"publisher","first-page":"108189","DOI":"10.1016\/j.clineuro.2024.108189","volume":"239","author":"W Wu","year":"2024","unstructured":"Wu W, Lu X, Zhang L, Hong D (2024) Effectiveness and safety of different catechol-o-methyl transferase inhibitors for patients with parkinson\u2019s disease: Systematic review and network meta-analysis. Clin Neurol Neurosurg 239:108189. https:\/\/doi.org\/10.1016\/j.clineuro.2024.108189 Epub 2024 Feb 23. PMID: 38437773","journal-title":"Clin Neurol Neurosurg"}],"container-title":["Journal of Neural Transmission"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00702-026-03278-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00702-026-03278-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00702-026-03278-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T02:03:20Z","timestamp":1794017000000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00702-026-03278-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,12]]},"references-count":42,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2026,10]]}},"alternative-id":["3278"],"URL":"https:\/\/doi.org\/10.1007\/s00702-026-03278-x","relation":{},"ISSN":["0300-9564","1435-1463"],"issn-type":[{"value":"0300-9564","type":"print"},{"value":"1435-1463","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,12]]},"assertion":[{"value":"27 June 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 August 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 September 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The meeting has been supported by Bial.","order":1,"name":"Ethics","label":"Conflict of interest","group":{"name":"EthicsHeading","label":"Declarations"}}]}}